Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models

Although botulinum neurotoxin serotype A (BoNT/A) products are common treatments for various disorders, there is only one commercial BoNT/B product, whose low potency, likely stemming from low affinity toward its human receptor synaptotagmin 2 (hSyt2), has limited its therapeutic usefulness. We expr...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Sci Adv
Hoofdauteurs: Elliott, Mark, Favre-Guilmard, Christine, Liu, Sai Man, Maignel, Jacquie, Masuyer, Geoffrey, Beard, Matthew, Boone, Christopher, Carré, Denis, Kalinichev, Mikhail, Lezmi, Stephane, Mir, Imran, Nicoleau, Camille, Palan, Shilpa, Perier, Cindy, Raban, Elsa, Zhang, Sicai, Dong, Min, Stenmark, Pål, Krupp, Johannes
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Association for the Advancement of Science 2019
Onderwerpen:
Research Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6357751/
https://ncbi.nlm.nih.gov/pubmed/30746458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aau7196
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items